Michael Pehl joined ADCendo as Chief Executive Officer in June 2021. Michael has over 25 years of international biotechnology and oncology leadership experience in both the US and Europe.
Co-founder & CFO
Henrik Stage is an experienced biotech-entrepreneur, active in several biotech companies, and was previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014.
PhD, Co-founder & COO
Christoffer F. Nielsen got his PhD in nanomedicine from the iNANO center at Aarhus University in 2012, having worked on development of methods for antibody-mediated delivery …
Lars Henning Engelholm
PhD & Co-founder
Lars H. Engelholm got his PhD in biochemistry from University of Copenhagen in 2001, and today he is a group leader at The Finsen Laboratory. Already early in his career …
PhD, DSc & Co-founder
Niels Behrendt is a Doctor of Science and PhD from the University of Copenhagen. He has been active in cancer research for more than 20 years and has particular expertise …
PhD & Senior scientific project manager
Sander van Putten
PhD & Senior scientific project manager
MSc & Research Scientist
Cand.med.vet. & Research Scientist
BSc.med.vet. & Student Helper
M.D., D.Phil. & Chair
John Haurum is a Non-executive Director in European biotech companies: Adcendo, Agomab, CatalYm, Neophore, Storm, Synact, Synklino …
PhD – Novo
Jeroen Bakker is currently a Principal at Novo Holdings and is part of the Novo Seeds team focusing on company creation and early-stage financings …
PhD – Ysios Capital
Joël Jean-Mariet is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology in 2001 and was its CEO until it was …
PhD – RA Capital
Rez Halse is a Partner, RA Ventures at RA Capital Management. Rez’s primary responsibility is to lead early-stage private investments in, and …
MD PhD – HealthCap
Mårten Steen is a partner of HealthCap. Previously, he has worked with business development at Merck Serono focusing on both product and technology …
Sanne de Jongh
MSc – Gilde Healthcare
Sanne de Jongh is Investment Manager at Gilde Healthcare, where she focuses on the firms’ investment activities in the biopharmaceutical sector. She …
Lars H. Engelholm
PhD – Founder director
Lars H. Engelholm got his PhD in biochemistry from University of Copenhagen in 2001, and today he is a group leader at The Finsen Laboratory. Already early …
Former CSO and executive at ImmunoGen
Honorary Professor, Queen’s University Belfast, Northern Ireland, UK.
Dr. John Lambert has a longstanding and well recognized history working in the ADC field. In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics, before joining ImmunoGen in 1987. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity until retirement. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla®, as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. In 2018, he was appointed as an Honorary Professor of Queen’s University Belfast, Northern Ireland, UK.
Murray Yule is a UK certified oncologist trained in Addenbrookes Hospital Cambridge and the Texas Medical Center with more than eighteen years experience in the pharma industry with the last ten years spent working in European Biotecnology companies. He has a deep experience in translational oncology and early stage clinical studies of novel biologics including ADCs in solid tumours through his experience at NBE Therapeutics and Axl directed therapies at ADC therapeutics.
Dr. de Groot has a track record in creating and capturing value, as biotech entrepreneur, business development executive and transactor. His profile blends biotech entrepreneurship mentality with hands-on big pharma experience in licensing, acquisitions and venturing. Dr. de Groot founded and led the ADC company Syntarga from inception to exit (Trade Sale). Syntarga discovered and developed [vic-]trastuzumab duocarmazine (SYD985), an ADC drug candidate currently in Phase 3 clinical development.